Ignite Creation Date:
2025-12-24 @ 11:47 PM
Ignite Modification Date:
2026-01-05 @ 6:03 PM
Study NCT ID:
NCT03135951
Status:
COMPLETED
Last Update Posted:
2020-11-13
First Post:
2017-04-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Sponsor:
Spectrum Pharmaceuticals, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-05-11
Start Date Type:
ACTUAL
Primary Completion Date:
2018-02-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-05-18
Completion Date Type:
ACTUAL
First Submit Date:
2017-04-20
First Submit QC Date:
None
Study First Post Date:
2017-05-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-11-11
Last Update Post Date:
2020-11-13
Last Update Post Date Type:
ACTUAL